chi-square tests with a bonferroni correction for multiple comparisons (SAS institute)
SAS institute is a verified supplier 
90
Structured Review
SAS institute
chi-square tests with a bonferroni correction for multiple comparisons
Chi Square Tests With A Bonferroni Correction For Multiple Comparisons, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/chi-square+tests+with+a+bonferroni+correction+for+multiple+comparisons/chi+square+tests+with+a+bonferroni+correction+for+multiple+comparisons/pm31812502-60-9-17
Average 90 stars, based on 1 article reviews
Chi Square Tests With A Bonferroni Correction For Multiple Comparisons, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/chi-square+tests+with+a+bonferroni+correction+for+multiple+comparisons/chi+square+tests+with+a+bonferroni+correction+for+multiple+comparisons/pm31812502-60-9-17
Average 90 stars, based on 1 article reviews
chi-square tests with a bonferroni correction for multiple comparisons - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
other:Article Title: FDA's Unimproved Enforcement of Postmarketing Requirements and Commitments: Implications for Providers and Patients. Article Snippet: Background: The 2007 reauthorization of the Prescription Drug User Fee Act empowered the Food and Drug Administration (FDA) to require and enforce postmarketing studies to monitor the safety of prescription drugs, an increasing number of which are approved under expedited development or review programs.. However, compliance rates for postmarketing requirements are low, and the FDA has not exercised its enforcement authority, allowing the very safety concerns that prompted the expansion of its power to continue.. Prior evaluations have found that the FDA lacks reliable, timely, and readily accessible data for tracking postmarket safety issues, and that it has failed to enforce the postmarket surveillance measures it requires of the pharmaceutical industry. |